Construction of a Prognostic Model for Hepatocellular Carcinoma Based on Macrophage Polarization-Related Genes

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6. doi:10.1038/s41572-020-00240-3
   PubMed Web of Science ®Google Scholar
• Huang A, Yang X-R, Chung W-Y, et al. Targeted therapy for hepatocellular carcinoma. Signal Transduct Target Ther. 2020;5(1):146. doi:10.1038/s41392-020-00264-x
   PubMed Web of Science ®Google Scholar
• Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;150(4):835–853. doi:10.1053/j.gastro.2015.12.041
   PubMed Web of Science ®Google Scholar
• Jacome AA, Castro ACG, Vasconcelos JPS, et al. Efficacy and safety associated with immune checkpoint inhibitors in unresectable hepatocellular carcinoma: a meta-analysis. JAMA Network Open. 2021;4(12):e2136128. doi:10.1001/jamanetworkopen.2021.36128
   PubMed Web of Science ®Google Scholar
• Sonbol MB, Riaz IB, Naqvi SAA, et al. Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: a Systematic Review and Network Meta-analysis. JAMA Oncol. 2020;6(12):e204930. doi:10.1001/jamaoncol.2020.4930
   PubMed Web of Science ®Google Scholar
• Peng H, Zhu E, Zhang Y. Advances of cancer-associated fibroblasts in liver cancer. Biomark Res. 2022;10(1):59. doi:10.1186/s40364-022-00406-z
   PubMed Web of Science ®Google Scholar
• Baglieri J, Brenner DA, Kisseleva T. The role of fibrosis and liver-associated fibroblasts in the pathogenesis of hepatocellular carcinoma. Int J Mol Sci. 2019;20(7):1723. doi:10.3390/ijms20071723
   PubMed Web of Science ®Google Scholar
• Pineiro Fernandez J, Luddy KA, Harmon C, et al. Hepatic tumor microenvironments and effects on NK cell phenotype and function. Int J Mol Sci. 2019;20(17):4131. doi:10.3390/ijms20174131
   PubMed Web of Science ®Google Scholar
• Chen H, Zhou X-H, Li J-R, et al. Neutrophils: driving inflammation during the development of hepatocellular carcinoma. Cancer Lett. 2021;522:22–31. doi:10.1016/j.canlet.2021.09.011
   PubMed Web of Science ®Google Scholar
• Wang Z, Wang Y, Gao P, et al. Immune checkpoint inhibitor resistance in hepatocellular carcinoma. Cancer Lett. 2023;555:216038. doi:10.1016/j.canlet.2022.216038
   PubMed Web of Science ®Google Scholar
• Zhang J, Han H, Wang L, et al. Overcoming the therapeutic resistance of hepatomas by targeting the tumor microenvironment. Front Oncol. 2022;12:988956. doi:10.3389/fonc.2022.988956
   PubMed Web of Science ®Google Scholar
• Tian Z, Hou X, Liu W, et al. Macrophages and hepatocellular carcinoma. Cell Biosci. 2019;9:79. doi:10.1186/s13578-019-0342-7
   PubMed Web of Science ®Google Scholar
• Cheng K, Cai N, Zhu J, et al. Tumor-associated macrophages in liver cancer: from mechanisms to therapy. Cancer Commun. 2022;42(11):1112–1140. doi:10.1002/cac2.12345
   Web of Science ®Google Scholar
• He Z, Zhang S. Tumor-associated macrophages and their functional transformation in the hypoxic tumor microenvironment. Front Immunol. 2021;12:741305. doi:10.3389/fimmu.2021.741305
   PubMed Web of Science ®Google Scholar
• Tamura R, Tanaka T, Yamamoto Y, et al. Dual role of macrophage in tumor immunity. Immunotherapy. 2018;10(10):899–909. doi:10.2217/imt-2018-0006
   PubMed Web of Science ®Google Scholar
• Wu K, Lin K, Li X, et al. Redefining tumor-associated macrophage subpopulations and functions in the tumor microenvironment. Front Immunol. 2020;11:1731. doi:10.3389/fimmu.2020.01731
   PubMed Web of Science ®Google Scholar
• Boutilier AJ, Elsawa SF. Macrophage polarization states in the tumor microenvironment. Int J Mol Sci. 2021;22(13):6995. doi:10.3390/ijms22136995
   PubMed Web of Science ®Google Scholar
• Mehla K, Singh PK. Metabolic regulation of macrophage polarization in cancer. Trends Cancer. 2019;5(12):822–834. doi:10.1016/j.trecan.2019.10.007
   PubMed Web of Science ®Google Scholar
• Li R, Zhao W, Liang R, et al. Identification and validation of a novel tumor microenvironment-related prognostic signature of patients with hepatocellular carcinoma. Front Mol Biosci. 2022;9:917839. doi:10.3389/fmolb.2022.917839
   PubMed Web of Science ®Google Scholar
• Zhao Y, Li M, Yang Y, et al. Identification of macrophage polarization-related genes as biomarkers of chronic obstructive pulmonary disease based on bioinformatics analyses. Biomed Res Int. 2021;2021:9921012. doi:10.1155/2021/9921012
   PubMed Web of Science ®Google Scholar
• Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinf. 2013;14:7. doi:10.1186/1471-2105-14-7
   PubMed Web of Science ®Google Scholar
• Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinf. 2008;9:559. doi:10.1186/1471-2105-9-559
   PubMed Web of Science ®Google Scholar
• Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550. doi:10.1186/s13059-014-0550-8
   PubMed Web of Science ®Google Scholar
• Yu G, Wang L-G, Han Y, et al. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284–287. doi:10.1089/omi.2011.0118
   PubMed Web of Science ®Google Scholar
• Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33(1):1–22. doi:10.18637/jss.v033.i01
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Marchesi F, et al. Macrophages as tools and targets in cancer therapy. Nat Rev Drug Discov. 2022;21(11):799–820. doi:10.1038/s41573-022-00520-5
   PubMed Web of Science ®Google Scholar
• Pu Y, Ji Q. Tumor-associated macrophages regulate PD-1/PD-L1 Immunosuppression. Front Immunol. 2022;13:874589. doi:10.3389/fimmu.2022.874589
   PubMed Web of Science ®Google Scholar
• Zhou D, Luan J, Huang C, et al. Tumor-associated macrophages in hepatocellular carcinoma: friend or foe? Gut Liver. 2021;15(4):500–516. doi:10.5009/gnl20223
   PubMed Web of Science ®Google Scholar
• Shirabe K, Mano Y, Muto J, et al. Role of tumor-associated macrophages in the progression of hepatocellular carcinoma. Surg Today. 2012;42(1):1–7. doi:10.1007/s00595-011-0058-8
   PubMed Web of Science ®Google Scholar
• Matsubara T, Kanto T, Kuroda S, et al. TIE2-expressing monocytes as a diagnostic marker for hepatocellular carcinoma correlates with angiogenesis. Hepatology. 2013;57(4):1416–1425. doi:10.1002/hep.25965
   PubMed Web of Science ®Google Scholar
• Gorrin-Rivas MJ, Arii S, Mori A, et al. Implications of human macrophage metalloelastase and vascular endothelial growth factor gene expression in angiogenesis of hepatocellular carcinoma. Ann Surg. 2000;231(1):67–73. doi:10.1097/00000658-200001000-00010
   PubMed Web of Science ®Google Scholar
• Hou ZH, Xu X-W, Fu X-Y, et al. Long non-coding RNA MALAT1 promotes angiogenesis and immunosuppressive properties of HCC cells by sponging miR-140. Am J Physiol Cell Physiol. 2020;318(3):C649–C663. doi:10.1152/ajpcell.00510.2018
   PubMed Web of Science ®Google Scholar
• Hasita H, Komohara Y, Okabe H, et al. Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma. Cancer Sci. 2010;101(8):1913–1919. doi:10.1111/j.1349-7006.2010.01614.x
   PubMed Web of Science ®Google Scholar
• Watkins LR, Orlandi C. Orphan G Protein coupled receptors in affective disorders. Genes. 2020;11(6):694. doi:10.3390/genes11060694
   PubMed Web of Science ®Google Scholar
• Lv X, Li L, Lv L, et al. HOXD9 promotes epithelial-mesenchymal transition and cancer metastasis by ZEB1 regulation in hepatocellular carcinoma. J Exp Clin Cancer Res. 2015;34:133. doi:10.1186/s13046-015-0245-3
   PubMed Web of Science ®Google Scholar
• Wang J, Ding Z-W, Chen K, et al. A predictive and prognostic model for hepatocellular carcinoma with microvascular invasion based TCGA database genomics. BMC Cancer. 2021;21(1):1337. doi:10.1186/s12885-021-09047-1
   PubMed Web of Science ®Google Scholar
• Long J, Zhang L, Wan X, et al. A four-gene-based prognostic model predicts overall survival in patients with hepatocellular carcinoma. J Cell Mol Med. 2018;22(12):5928–5938. doi:10.1111/jcmm.13863
   PubMed Web of Science ®Google Scholar
• Zhang Z, Li J, He T, et al. Two predictive precision medicine tools for hepatocellular carcinoma. Cancer Cell Int. 2019;19:290. doi:10.1186/s12935-019-1002-z
   PubMed Web of Science ®Google Scholar
• Chen C, Liu YQ, Qiu SX, et al. Five metastasis-related mRNAs signature predicting the survival of patients with liver hepatocellular carcinoma. BMC Cancer. 2021;21(1):693. doi:10.1186/s12885-021-08431-1
   PubMed Web of Science ®Google Scholar
• Zhang F-P, Huang Y-P, Luo W-X, et al. Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment. World J Gastroenterol. 2020;26(2):134–153. doi:10.3748/wjg.v26.i2.134
   PubMed Web of Science ®Google Scholar
• Meng D, Luo M, Liu B. The Role of CLEC-2 and Its Ligands in Thromboinflammation. Front Immunol. 2021;12:688643. doi:10.3389/fimmu.2021.688643
   PubMed Web of Science ®Google Scholar
• Hu K, Wang Z-M, Li J-N, et al. CLEC1B expression and PD-L1 expression predict clinical outcome in hepatocellular carcinoma with tumor hemorrhage. Transl Oncol. 2018;11(2):552–558. doi:10.1016/j.tranon.2018.02.010
   PubMed Web of Science ®Google Scholar
• Liang X, Song F, Fang W, et al. CLEC1B is a promising prognostic biomarker and correlated with immune infiltration in hepatocellular carcinoma. Int J Gen Med. 2022;15:5661–5672. doi:10.2147/IJGM.S363050
   PubMed Web of Science ®Google Scholar
• Zhang G, Zhang K, Zhao Y, et al. A novel stemness-hypoxia-related signature for prognostic stratification and immunotherapy response in hepatocellular carcinoma. BMC Cancer. 2022;22(1):1103. doi:10.1186/s12885-022-10195-1
   PubMed Web of Science ®Google Scholar
• Ding S, Wang X, Lv D, et al. EBF3 reactivation by inhibiting the EGR1/EZH2/HDAC9 complex promotes metastasis via transcriptionally enhancing vimentin in nasopharyngeal carcinoma. Cancer Lett. 2022;527:49–65. doi:10.1016/j.canlet.2021.12.010
   PubMed Web of Science ®Google Scholar
• Rodger EJ, Chatterjee A, Stockwell PA, et al. Characterisation of DNA methylation changes in EBF3 and TBC1D16 associated with tumour progression and metastasis in multiple cancer types. Clin Clin Epigenet. 2019;11(1):114. doi:10.1186/s13148-019-0710-5
   PubMed Web of Science ®Google Scholar
• Liao D. Emerging roles of the EBF family of transcription factors in tumor suppression. Mol Cancer Res. 2009;7(12):1893–1901. doi:10.1158/1541-7786.MCR-09-0229
   PubMed Web of Science ®Google Scholar
• Kim J, Min SY, Lee HE, et al. Aberrant DNA methylation and tumor suppressive activity of the EBF3 gene in gastric carcinoma. Int, J, Cancer. 2012;130(4):817–826. doi:10.1002/ijc.26038
   PubMed Web of Science ®Google Scholar
• Tao YF, Xu L-X, Lu J, et al. Early B-cell factor 3 (EBF3) is a novel tumor suppressor gene with promoter hypermethylation in pediatric acute myeloid leukemia. J Exp Clin Cancer Res. 2015;34(1):4. doi:10.1186/s13046-014-0118-1
   PubMedGoogle Scholar
• Zhao LY, Niu Y, Santiago A, et al. An EBF3-mediated transcriptional program that induces cell cycle arrest and apoptosis. Cancer Res. 2006;66(19):9445–9452. doi:10.1158/0008-5472.CAN-06-1713
   PubMed Web of Science ®Google Scholar
• Hudson AJ, Ebers GC, Bulman DE. The skeletal muscle sodium and chloride channel diseases. Brain. 1995;118:547–563. doi:10.1093/brain/118.2.547
   PubMed Web of Science ®Google Scholar
• Wang Z, Embaye KS, Yang Q, et al. A novel metabolism-related signature as a candidate prognostic biomarker for hepatocellular carcinoma. J Hepatocell Carcinoma. 2021;8:119–132. doi:10.2147/JHC.S294108
   PubMed Web of Science ®Google Scholar
• Yan Y, He W, Chen Y, et al. Comprehensive analysis to identify the encoded gens of sodium channels as a prognostic biomarker in hepatocellular carcinoma. Front Genet. 2021;12:802067. doi:10.3389/fgene.2021.802067
   PubMedGoogle Scholar